Register Today for Cannabis Science Conference Spring!

On this month’s episode, we are joined by James Schwartz, BSN, LNC CEO of Cascade High Organics

 Ep 13: Psychedelic Science: Understanding Emerging Research and Potential Therapeutic Applications

Don't miss our November/December issue focused on veterans and medical cannabis advocacy

Cannabis Patient Care November/December

Don't miss our October issue focused on pediatric cancer

Cannabis Patient Care October

Check out our July/August issue focused on autoimmune diseases

Cannabis Patient Care July/August

Professor Raphael Mechoulam, a researcher at Hebrew University’s School of Pharmacy, was a world leader in cannabinoid research. Mechoulam’s groundbreaking work included the isolation of tetrahydrocannabinol (THC) in the 1960s along with several other cannabinoids, as well as the discovery of endocannabinoids in the 1990s (1,2). He coauthored the book 

"Most of the human and scientific knowledge about cannabis was collected thanks to Professor Mechoulam,” said Professor Asher Cohen, President of Hebrew University (1). “He paved the way for a series of studies in the field and called for scientific collaboration among different researchers. He was a sharp-minded, groundbreaking, and charismatic intellectual. This is a sad day for the academic community, and I extend my heartfelt condolences to the family. May his memory be a blessing."

Professor Mechoulam was born in Sofia, Bulgaria in 1930, and after surviving the Holocaust, he immigrated to Israel with his family in 1949. Mechoulam completed his degree in biochemistry in 1953 at Hebrew University, began his research in cannabinoids at the Weizmann Institute of Science in Israel in 1962, and then joined the Hebrew University in 1966, where he continued to study the compounds found in cannabis (1). He was appointed as a full-time professor in the 1970s, then was appointed to the Lionel Jacobson Chair in Medicinal Chemistry, and between 1979-1982 he served as the Rector of the Hebrew University.

Mechoulam was one of the founding members of the International Association for Cannabinoid Medicines. In 1999, he was appointed the President of the International Cannabinoid Research Society (ICRS), a position he held until 2002. The ICRS presents their highest award, the "Raphael Mechoulam Award," each year (3). Additionally, he served as the Head of the Natural Sciences Division at the Israel Academy of Sciences and Humanities.

“This is a very sad day for me, for the science community, and for the cannabis community,” said Dr. David “Dedi” Meiri, associate professor at Technion Israel Institute of Technology, (4). “Professor Raphael Mechoulam, or as we called him Raphi, was one of the greatest scientists I ever met and was my teacher and mentor in many aspects. I truly believe he was deserving of a Nobel prize! Thank you Raphi for all the great things you did and discovered in your life and thanks for all the help and support you gave me. Rest in peace my dear friend.”

Throughout his life, Mechoulam received dozens of awards, honors, and decorations, including the Israel Prize for Chemistry (2000), the EMET Prize (2012), Rothschild Prize in Chemical Sciences and Physical Sciences (2012), the Harvey Prize of the Technion Israel Institute of Technology (2019), plus several honorary doctorates (3).

We thank you for your numerous contributions to the science of cannabis, Professor Mechoulam. We are eternally grateful for your research, dedication, and legacy.

Special thanks to Ilanit Liberman for providing additional information and quotes.

https://www.afhu.org/2023/03/10/hebrew-university-prof-raphael-mechoulam-father-of-cannabis-research-dies-at-92/

https://www.analyticalcannabis.com/news/raphael-mechoulam-father-of-cannabis-science-dies-at-age-92-314671

https://www.icrs.co/INMEMORIAM/Raphael.Mechoulam.Obituary.html

https://www.linkedin.com/feed/update/urn:li:activity:7039897744307544064/

Articles

A pioneer in global cannabis research, Professor Raphael Mechoulam died March 9th, 2023 in Israel at the age of 92.

In Memoriam: Raphael Mechoulam, “Father of Cannabis Research”

 (CSC), the premier cannabis science conference event focusing on analytical science, medical cannabis, cultivation, and psychedelics, announced today the return of their groundbreaking event to Portland, Oregon from April 19-21, 2023, a location which is perfectly positioned as a hotbed of cannabis activity and interest, and the epicenter of the new and emerging psychedelic market.

“Portland, Oregon is a natural fit for our Spring 2023 Cannabis Science Conference, with its established cannabis and medical markets, and openness toward emerging markets such as psychedelics,” said Megan L’Heureux, spokesperson for CSC, and the group editorial director of 

 magazines. “CSC’s goal is to spread information and empowerment through education, and we are bringing a hard-hitting team of professional experts to share knowledge and have in-depth conversations about how to move these niche industries forward. We look forward to tackling topics like using psychedelics and medical cannabis to help veterans and other patient demographics as well as our core topic areas focused on analytical testing and cultivation. Our agenda will hit every topic our audience has been asking to learn more about.”

The agenda will include four main program tracks, with professional expert chairs including Analytical chair Dr. Julie Kowalski, a technical consultant serving the cannabis and hemp testing markets; Cultivation chair Dr. Zacariah L. Hildenbrand, who sits on the Editorial Advisory Board of 

; Medical chair Cherissa Jackson, who served 23 years of active-duty military service with 10 years as a US Air Force Nurse; and Psychedelics chair Dr. Denise Vidot, an epidemiologist at the University of Miami where she is Founder of the International Cannabis and Psychedelic Research Collaborative.

The show will feature several key sessions, including:

“Low and Ultra-Low Doses of Cannabinoids: Are We Missing the Sweet Spot?” by Dr. Dustin Sulak, DO, Healer.com

“MDMA/Psychedelic-Assisted Therapy: The Path to Potential FDA Approval” by Dr. Sue Sisley, MD, President of Scottsdale Research Institute (SRI) and President/Founder of Field to Healed Foundation

A panel discussion on “Results from the First NIH Funded Population-based Study of Medical Marijuana”

A panel discussion on “Quality Assurance and Safety in Cannabis, Psilocybin, and Hemp”

, and a conversation on the increasing numbers of veterans are turning to cannabis as a safer alternative to pharmaceuticals by filmmaker Steve Ellmore

For the full show agenda and to register, please visit the 

The 2023 Portland show will include four tracks–analytical science, medical cannabis, cultivation, psychedelics–plus a discussion on medical cannabis for veterans, and more!

Cannabis Science Conference Returns to Portland, Oregon with Renewed Focus on Analytical, Medical, Cultivation, and Psychedelic Scientific Insights

On March 3, 2023, the US Department of Justice introduced a form for those who qualify under last year’s pardon for cannabis possession to obtain a certificate proving their pardon (1). “On Oct. 6, 2022, the President announced a full, unconditional and categorical pardon for prior federal and DC offenses of simple possession of marijuana,” reads the official announcement from the Justice Department (1). “The President’s pardon lifts barriers to housing, employment and educational opportunities for thousands of people with those prior convictions.”

To qualify for the pardon, a person must have been charged or convicted in a federal or District of Columbia (DC) Superior Court of simple possession of cannabis, among other qualifications. Those who were convicted of state offenses or of selling cannabis do not qualify (2). The Pardon Attorney’s office estimates that the form could take anywhere from 20 minutes to two and a half hours to complete, and that at least 20,000 applicants could apply for certificates (2).

 blog on the announcement, Americans for Safe Access (ASA) reiterated that they have been fighting for the past 20 years to protect medical cannabis patients and providers against unjust arrests. “Though we don’t know of anyone currently incarcerated who will be freed by this mass pardoning it will improve the lives of plenty of people with one of these convictions lingering in a criminal record,” wrote ASA (3). “Those individuals will have their civil rights; like voting, assuming political office or serving on a jury restored by this pardon and it will also make it easier for them to find work, receive professional licensing and generally stop being penalized for that conviction. We would love to see not only more federal pardons but also more Governors offering pardons to those convicted for cannabis ‘crimes’ that are no longer illegal in their state.”

Learn more details about the qualifications or complete the form 

https://www.justice.gov/opa/pr/justice-department-announces-application-form-marijuana-pardon-certificates

https://www.marijuanamoment.net/justice-department-launches-marijuana-pardon-certificate-application/

In early March 2023, the US Justice Department launched an online application for individuals who were pardoned for simple possession of cannabis under President Biden's October 6, 2022 proclamation. Applicants can now receive a certificate of proof of their pardon.

US Justice Department Launches Online Application for Certificate of Proof of Cannabis Possession Pardon

In early March 2023, the Arizona Senate approved a bill that would cut the cost—both initially and the two-year renewal—for a medical cannabis card from $150 down to $50, while making the card free for veterans (1,2). It would also add post-traumatic stress disorder (PTSD) and autism spectrum disorder as qualifying medical conditions, and would require packaging for medical cannabis products to have a QR code with information such as health warnings.

"We felt it was really important to provide the veterans in the state access to medical marijuana as they see needed," said Ann Torrez, executive director of the Arizona Dispensaries Association (2). "And, in addition to that, with the change in medical conditions to include post-traumatic stress disorder, we just thought that this now is the right time to make sure that the access becomes even more available."

The bill must pass the House before being presented to the governor of Arizona.

https://norml.org/blog/2023/03/08/state-policy-weekly-update-3-8-2023/

https://www.thecentersquare.com/arizona/article_7c5e692c-ba09-11ed-b29b-674282525c40.html

If passed into law, SB 1466 would reduce cost of renewing a medical cannabis card in Arizona, among other changes. The bill passed the senate with bipartisan approval 24 to 6 on March 2, 2023 (1).

Arizona Senate Approves Bill to Lower Medical Cannabis Card Costs and Increase Accessibility for Veterans

In late February 2023, medical cannabis patient Jakie Hanan filed a civil lawsuit in Arkansas against three cannabis cultivators and one testing laboratory alleging collaboration to inflate tetrahydrocannabinol (THC) levels in cannabis products. The suit names cultivators BOLD Team LLC, Osage Creek Cultivation, LLC, and Natural State Medicinals (NSM) and testing laboratory Steep Hill in the litigation, alleging that Steep Hill inflated the THC listed on the cultivators’ labels (1).

Hanan, who had been prescribed medical cannabis for his chronic pain, alleges that in 2022 he purchased cannabis products cultivated from the three growers, but they did not adequately provide the relief he expected so he had the products tested (2). Hanan tested some cannabis at a different laboratory and found that the Steep Hill’s test results on the product labels significantly exaggerated THC content (2). “To further investigate, Plaintiff, and others, tested products from Arkansas cultivators using multiple state-approved labs,” the suit reads. “For flower samples, over thirty (30) potency results were collected and compared, primarily from Jan 2021 to February 2023…Excluding Steep Hill, local labs produced results within 10% or better of each other. Steep Hill’s results averaged 25%+ higher than the other labs,” (2).

“Marijuana flower with higher concentration of THC is more valuable,” the suit continues (2). “So there is incentive to exaggerate the THC content of flower — it can be sold for more money. As a result, cultivators often choose a lab that reports the highest THC value, a phenomenon known as ‘lab shopping.’”

Steep Hill denied the allegations (1). “We are an ISO-accredited lab and have our processes audited each and every year by reputable 3rd parties, which we’ve done since we’ve been in business,” said Steep Hill CEO and co-owner Brandon Thornton (1). “We stand behind the quality, integrity and efficacy of our lab, employees and impartial test results.”

In July 2022, Hanan had filed a federal class-action lawsuit against these four companies with allegations under the Racketeer Influenced and Corrupt Organizations (or RICO) Act (3).

https://arkansasadvocate.com/2023/02/27/patient-sues-arkansas-medical-marijuana-growers-lab-over-alleged-thc-inflation/

https://arkansasadvocate.com/wp-content/uploads/2023/02/thc_inflation_suit.pdf

https://mjbizdaily.com/4-arkansas-marijuana-companies-hit-with-rico-suit-over-alleged-thc-inflation/

A civil lawsuit filed in Arkansas by a medical cannabis patient alleges that three cannabis growers and one testing laboratory inflated the amount of tetrahydrocannabinol (THC) in numerous cannabis products.

Civil Lawsuit Accuses Arkansas' Largest Cannabis Testing Laboratory of Conspiring with Cultivators to Inflate THC Levels

According to an announcement from the Yale School of Medicine (New Haven, Connecticut), a new research center called the Yale Center for the Science of Cannabis and Cannabinoids will use a multidisciplinary approach to study the acute and chronic effects of cannabis and cannabinoids on neurodevelopment and mental health (1). This new center will be directed by Deepak Cyril D’Souza, Professor of Psychiatry, and an expert in the pharmacology of cannabinoids (1). Notably, Dr. D’Souza also serves on the Physicians Advisory Board for Connecticut’s Medical Marijuana Program (2).

“Right now, the center has a broad interest in the impact of cannabis on the developing brain and on mental health,” Dr. D’Souza said in an interview with 

 (1). “But that doesn’t mean there aren’t other topics of interest and relevance, and as we greenlight pilot projects, the center’s goals may become more focused. At the end of the day, we are doing this to generate the highest quality information that people can use to make decisions at many different levels—individuals, towns, public health departments, states, for example.”

Dr. D’Souza has been involved in educating the general public about the relationship between cannabis and psychosis, and also answered an interview question about whether the center is going to be for or against cannabis. “My answer is that we just want to collect information on the science of cannabis and cannabinoids. We want to advance the science,” he said (3).

Dr. D’Souza also said that more information will be coming soon about applications for pilot funding and on how the public can participate in studies.

Connecticut legalized the medical use of cannabis in 2012 and sales of legal recreational cannabis began earlier this year, following adult use legalization in 2021.

https://medicine.yale.edu/news-article/ysm-to-establish-yale-center-for-the-science-of-cannabis-and-cannabinoids/

https://medicine.yale.edu/profile/deepak-dsouza/

https://news.yale.edu/2023/02/22/yale-digs-science-cannabis

In early 2023, Yale School of Medicine announced the foundation of a new center for cannabis research. The center’s inaugural director recently provided commentary on the goals and direction of the research.

More Details on Yale University’s New Research Center for Cannabis and Mental Health

Scientists at England’s University of Oxford recently launched a global trial to study the potential effects of cannabidiol (CBD) on psychosis (1). Coordinated by Oxford’s department of psychiatry, the study will involve 35 centers, mostly in Europe and North America. The stratification and treatment in early psychosis (Step) program will study 1000 patients, including those who are at high risk of psychosis, those who with a first episode of psychosis, and those who have not responded well to conventional treatments.

“Cannabidiol is one of the most promising new treatments for people with psychosis,” said Oxford professor Philip McGuire, who is leading the trial (1). “Many people with psychosis are open to trying cannabidiol and previous smaller-scale studies have indicated that it has beneficial effects. As well as treating psychosis that is already established, the study will also investigate whether cannabidiol can prevent the onset of psychosis in people at high risk of developing it.”

The study was awarded £16.5 million by Wellcome, a global charitable foundation supporting health research (2). The CBD for the study was provided at no cost by Jazz Pharmaceuticals, a biopharmaceutical company based in Ireland (3). The form of CBD used is Epidiolex, known in Europe as Epidyolex.

“This exciting programme will help us to find out if cannabidiol is effective at treating psychosis at various stages by testing it at scale,” said Lynsey Bilsland, the head of mental health translation at Wellcome (1). “While antipsychotics are commonly used to treat psychosis, they can have significant side effects, patients often stop taking them, and they don’t work for everyone. This means that it is important that we explore avenues such as this one for new therapies. In addition, as part of these trials the researchers are aiming to identify biomarkers – biological signposts – which would indicate that a patient might respond well to the treatment. This will allow for greater personalisation of treatment in the future.”

Currently in the United Kingdom, CBD is prescribed for only a few conditions, including epilepsy and vomiting or nausea caused by chemotherapy (1).

https://www.theguardian.com/society/2023/feb/16/global-oxford-study-trial-cannabis-based-medicine-treatment-psychosis-cbd

Recently, the University of Oxford began an international study to examine the potential therapeutic benefits of cannabidiol (CBD) in treating psychosis or psychotic symptoms.

Cannabidiol for Potentially Treating Psychosis: International Study Launched by University of Oxford

On February 14, 2023, House Representatives Lou Correa (D-CA) and Jack Bergman (R-MI) filed a bill called the “VA Medicinal Cannabis Research Act” that would direct Veterans Affairs (VA) to research medical cannabis and its potential to treat veterans’ post-traumatic stress disorder (PTSD) and chronic pain (1). This bill comes one week after bipartisan senators filed a similar bill (2).

“With the opioid crisis raging across America, it is imperative to the health and safety of our veterans that we find alternative treatments for chronic pain and service-related injuries,” said Correa (1).

“This will allow us to explore treatments for chronic pain and other ailments that our veterans face without the need for opiates,” Bergman said (1). “It will also ensure the medical safety of our veterans, providing secure pathways to pain alleviation instead of driving many to self-mediate where marijuana has been legalized.”

Previous versions of this bill date back to 2018, and this current iteration includes several revisions, including giving the VA the autonomy to determine whether it can oversee clinical trials into cannabis for chronic pain and PTSD (1). The latest version of the legislation also now requires an observation study to look at the experiences of veterans who've used cannabis for such treatment in the past, outside of the clinical trial context.

“VA uses evidence-based clinical guidelines to manage other pharmacological treatments of post-traumatic stress disorder, chronic pain, and substance use disorder because medical trials have found them effective,” said Pat Murray, director of national legislative service for Veterans of Foreign Wars (VFW) (1). “VA must expand research on the efficacy of non-traditional medical therapies, such as medicinal cannabis and other holistic approaches.”

https://www.marijuanamoment.net/bipartisan-house-members-file-veterans-medical-marijuana-research-bill-with-senate-companion-up-for-vote-this-week/

https://www.marijuanamoment.net/bipartisan-senators-file-revised-veterans-marijuana-research-bill-with-house-companion-set-to-drop-next-week/

The House and Senate introduced a revised bill to mandate Veterans Affairs (VA) to conduct research on the effects of medical cannabis on veterans with post-traumatic stress disorder (PTSD) and chronic pain.

House and Senate Introduce Bill to Direct Veterans Affairs to Study Medical Cannabis to Treat Certain Conditions

Can you tell us about your background and experience? What was the catalyst for starting your own cannabis education business?

: I’ve been a nurse for 10 years. I started my career working in oncology and bone marrow transplant at Johns Hopkins Hospital. I’m nationally certified in three specialties, the most recent being hospice and palliative care. I had a hospice patient last year who was having seizures and was unresponsive to five different seizure medications. I knew cannabis could help, but I had no idea what to give, how to dose, or where to start. I saw a need for a local expert who knew both the medical side and the cannabis side, and I decided I wanted to be that expert. I started going to conferences, webinars, online courses, and I’m currently in graduate school, working towards a master of science in medical cannabis therapeutics from Pacific College. During that time, I started a business as a cannabis nurse educator.

How do you bring together your diverse nursing experiences and background to guide each person’s individual journey with cannabis?

 The cannabis expertise is only part of what I offer. The actual nursing part is what has made me the compassionate educator that I am. Regardless of the specialty, nurses are responsible for educating patients on their disease and their treatment, so I have years of breaking down challenging medical concepts into ones that patients can understand. I use that experience to educate patients on how cannabis can help with their symptoms.

I’ve also leveraged that by making educational content on social media. I create short cannabis educational videos and explain difficult concepts in ways that people understand.

Why is being a cannabis nurse and educator important to you and your clients? What sorts of challenges do you have to overcome?

 With education comes empowerment, and I love being able to educate and empower my patients to take their health into their own hands and make their own decisions. The Western model of medicine strips patient autonomy and reduces health to a symptom and a pill. I teach patients how to tune in to how their body is feeling and medicate appropriately. I teach them how to manage symptoms with and without cannabis.

An interesting challenge is teaching patients how to check in with their body and their emotions, so they can learn how to medicate appropriately for what they’re feeling. I help them develop a mind-body awareness to help them learn to self-medicate effectively.

You offer lectures, workshops, webinars, products, a blog, and are active on social media. How receptive have audiences been to cannabis education? What are people most eager to learn?

 I’ve had a very positive experience creating cannabis educational content on social media. People are thirsty for accurate information from a trusted source. They’re thirsty for validation that cannabis really does help their attention-deficit/hyperactivity disorder (ADHD) and other conditions. They want to know how cannabis will help their cancer or their depression. People are thirsty for facts about cannabis.

I made it to 77,000 followers on TikTok before getting mass-reported and permanently banned over calling out synthetic cannabinoids. TikTok was extremely restrictive, and it was a challenge to actually promote my business and my products. Instagram and Facebook are far less restrictive, and I’ve had a lot of success educating and generating sales on those platforms.

What has been your biggest “Aha” moment so far?

 Seeing this graph at a conference and really visualizing how cannabis is less harmful than substances we consume daily or that are prescribed daily. This graph (1) made me question everything I had been taught in school about cannabis and other drugs. Some of the substances we were scared away from are actually safer than substances we’ve normalized.

https://doi.org/10.1111/j.1360-0443.2004.00744.x

You seem sensitive to the care and needs of patients who are children or older adults. What are some of the unique methods you use when approaching care with cannabis for these different patient populations?

 I approach pediatrics and seniors with both objectivity and empathy. No parent wants to give their kid anything that could harm them, and we’ve been told for 100 years that this plant is harmful. Many parents also want to stay away from pharmaceuticals and are opting for natural methods to help their kids. I present them with existing evidence we have on the condition as well as my own personal experience. Again, it’s about educating them and empowering them to make the best decision for their children.

When it comes to seniors, many of them are on multiple medications and are still looking for relief. They also need clear direction on what to take and how much, so I try to do that while also empowering them to learn how to dose themselves.

Your consultation offerings range from product questions to group sessions and consultation on severe illnesses. Why was that range of options important for you to offer?

 This is actually part of the business model that we just changed. In my experience, patients don’t want to pay to learn what to take in individual or group sessions. They just want to be told what will work best for their symptoms, and they’ll purchase the product. Since I have quality products to offer, we just launched free product guidance calls to give recommendations for those who are just looking for help for a single issue. We have the consultations for those with complex issues, such as those wanting to cut down their cannabis use or those needing help with children.

What are the most common questions you and Trusted Canna’s pharmacist are asked for help with?

 The most common question is, “what would help me with x…” or, “what can I give my kid for x?”

We have a pharmacist on board to help with medication interactions so that we can safely guide our patients, especially the seniors who are on multiple medications.

Where do you see the areas for the most growth for medical cannabis in the US? Do dispensary partnerships with cannabis nurses offer a significant solution?

 I firmly believe that medical professionals, specifically nurses, are one of the most underutilized resources in the industry. Who better to help guide a patient in their cannabis use than someone who knows both the medical side and the cannabis side and who’s been voted the most trusted profession in the country for 20 years now?

There’s a huge gap in education between the plant and the consumer. Budtenders can be helpful, and some are more knowledgeable than others, but in a recreational market, the medical patient is often forgotten and left to figure it out themselves. Also, there’s zero guidance on the hemp side, other than dismissal from medical professionals. Education of patients and healthcare providers would not only stimulate more growth in the industry, but it would foster more credibility and less stigma.

: We have a lot of plans! On the product side, we’re currently launching an entire tetrahydrocannabivarin (THCV) line, including full spectrum THCV oil, gummies, and mints! We’re currently testing suppositories on some patients with endometriosis and pelvic pain. On the education side, we’re about to start reaching out to health care facilities, pitching educational programs, and offering continuing education unit credits (CEUs) for nurses. Since we’re vendorized with the Veterans Affairs (VA), we’re also working on procuring government contracts to teach VA nurses about cannabis.

Do you have any final advice or insights you’d like to share?

 Thank you so much for interviewing me! I’m really excited to be at what feels like the ground floor of cannabis going mainstream. This of course wouldn’t be possible without the base that was laid by all of those who came before me, and I’m so thankful to be able to talk so freely about cannabis because of them.

https://onlinelibrary.wiley.com/doi/full/10.1111/j.1360-0443.2004.00744.x

A major focus area when it comes to medical cannabis is patient and healthcare education, or rather the lack of that education and rampant misinformation. When Megan Mbengue, BSN, RN, CHPN, saw this gap in educational resources firsthand for people who are looking to use cannabis as a treatment, she decided to launch Trusted Canna Nurse with a mission to break stigma through education. Voted a Cannabis Nurse Entrepreneur of the Year by Cannabis Nurses Networks in 2022, Mbengue and her team offer cannabinoid education, consultations, and a line of products for the spectrum of chronic illnesses. In this interview, Mbengue shares how and why she provides guidance as a cannabis nurse for symptoms of conditions such as ADHD, cancer, autism, chronic pain, and more. She also describes the difficulties presented by the lingering stigma of cannabis and explains her hopes for the role of nurses in medical cannabis.

Bridging the Gap Between Patient and Medical Cannabis: One Nurse Steps Up to the Challenge

In a recent press release (1), Medical Marijuana Inc., announced it took part in a preclinical study in collaboration with the Center for Research and Advanced Studies of Neurological Diseases at the XXI Century National Medical Center in Mexico demonstrating the ability of cannabidiol (CBD) to decrease extracellular glutamate levels that can lead to traumatic brain injuries.

“Through this controlled study, we were able to observe that the oral administration of cannabidiol during the seven days prior to an injury helped to avoid the over-release of glutamate that results from brain trauma, an effect associated with decreased mortality in neurons,” said the leader of the study Dr. Luisa Rocha (1). “In this study, it was also shown that the application of CBD helps sensorimotor improvement. In fact, pre-injury CBD treatment was sufficient to lessen the aftermath of traumatic brain injury.”

According to the press release (1), Medical Marijuana, Inc., is a cannabis company in the non-psychoactive cannabinoid space with a global portfolio of cannabinoid-based nutraceutical brands and a cannabinoid-based clinical research and botanical drug development sector. The preclinical study used Medical Marijuana Inc.’s real scientific hemp oil (RSHO) CBD product, which contained no tetrahydrocannabinol (THC).

Additionally, HempMeds, a subsidiary of Medical Marijuana Inc., recently participated in a study testing the effectiveness of hemp-based cannabidiol (CBD) in treating Parkinson’s Disease (1).

“The results of this study further proves the therapeutic value of plant-based CBD,” said Blake Schroeder, CEO of Medical Marijuana, Inc. (1). “While federally funded research institutions in the US have been slow to embrace cannabis-based research, Latin American institutions have been performing this type of research in conjunction with our company for years. We will continue to pursue research in Mexico as well as in Brazil, where we are pursuing pharmaceutical registration of our products.”

https://www.globenewswire.com/news-release/2023/02/06/2602167/0/en/Medical-Marijuana-Inc-Participates-in-Preclinical-Research-Study-on-Therapeutic-Benefits-of-CBD-on-Traumatic-Brain-Injuries.html

Cannabidiol (CBD) was recently studied in Mexico as a treatment for traumatic brain injury and Parkinson’s Disease.

Featured Content

Register Today for Cannabis Science Conference Spring!

Ep 13: Psychedelic Science: Understanding Emerging Research and Potential Therapeutic Applications

Cannabis Patient Care November/December

Cannabis Patient Care October

Cannabis Patient Care July/August